Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-003 in newly diagnosed metastatic renal cell carcinoma
NCT00272649Phase 2Completed
- Sponsor
- Argos Therapeutics
- Start
- Jan 2006
- Primary completion
- Feb 2012
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rocapuldencel-T in renal cell carcinoma (RCC), sponsored by Argos Therapeutics. Primary endpoints: Tumor response by RECIST at 24 weeks and T-cell responses to vaccination at 24 weeks. Started Jan 2006; status: completed.
02
Drugs
rocapuldencel-T
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00272649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272649.